Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

NCT06683937 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06683937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06683937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Completed
Start date
December 14, 2024
Completion date
July 18, 2025
Enrollment
327 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

immunocompromised patients, sars-cov-2 disease